This phenotype is characterized by increased secretion of OPG, suppression of protumoral and premetastatic activity of 4T1+ RANKL-expressing T cells, and a consequent reduction in tumor burden and bone metastases. The gene discussed is TNFRSF11B; the disease is neoplasm.